Literature DB >> 18528717

One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient.

Anna Enblom1, Beata Bergius Axelsson, Gunnar Steineck, Mats Hammar, Sussanne Börjeson.   

Abstract

OBJECTIVE: To describe the prevalence of nausea and vomiting during radiotherapy and to compare quality of life, psychological and functional status in patients experiencing or not experiencing nausea.
MATERIALS AND METHODS: A cross-sectional selection of 368 cancer patients treated with radiotherapy answered a questionnaire (=93% answering rate) regarding nausea, vomiting, actual use of and interest in antiemetic treatment, quality of life and psychological and functional status during the preceding week of radiotherapy. Mean age was 60 years and 66% were women. MAIN
RESULTS: Nausea was experienced by 39% (145) and vomiting by 7% (28) of patients in general, by 63% in abdominal or pelvic fields and by 48% in head/neck/brain fields. Abdominal/pelvic field (Relative risk (RR) 2.0), age < or = 40 years (RR 1.9) and previous nausea in other situations (RR 1.8) implied an increased risk for nausea. Antiemetics were used by 17% and 78% were interested in or wanted more information about acupuncture treatment against nausea. Of the 145 nauseous patients only 25% felt that antiemetics had helped them and 34% would have liked additional treatment, although the nausea intensity was mild in 72%. The nauseous patients reported lower well-being and quality of life, lower satisfaction with aspects of daily living and more frequent anxiety and depressed mood than the patients without nausea.
CONCLUSIONS: Of all patients undergoing radiotherapy, 39% experienced nausea and one third of them would have liked more treatment against the nausea. This study stresses the importance to identify and adequately treat patients with increased risk for nausea related to radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18528717     DOI: 10.1007/s00520-008-0445-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  50 in total

Review 1.  Management of radiation-induced nausea and vomiting.

Authors:  George G Abdelsayed
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

2.  Prophylactic tropisetron versus rescue tropisetron in fractionated radiotherapy to moderate or high emetogenic areas: a prospective randomized open label study in cancer patients.

Authors:  K Mystakidou; E Katsouda; A Linou; E Parpa; V Kouloulias; V Nikolaou; L Vlahos
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 3.  Nausea: the neglected symptom?

Authors:  Jan Foubert; Giel Vaessen
Journal:  Eur J Oncol Nurs       Date:  2005-03       Impact factor: 2.398

4.  Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.

Authors:  T R Spitzer; C J Friedman; W Bushnell; S R Frankel; J Raschko
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

Review 5.  Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy.

Authors:  K M Doherty
Journal:  Clin J Oncol Nurs       Date:  1999-07       Impact factor: 1.027

6.  The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy.

Authors:  R Lanciano; D M Sherman; J Michalski; A J Preston; K Yocom; C Friedman
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

Review 7.  Prevention of radiotherapy-induced emesis.

Authors:  G Tonini; B Vincenzi; D Santini; A La Cesa; E Finolezzi; N Onori; R D'Angelillo; A Baldi; L Trodella
Journal:  J Exp Clin Cancer Res       Date:  2003-03

8.  Measuring chemotherapy-induced nausea and emesis.

Authors:  Charles G Martin; Edward B Rubenstein; Linda S Elting; Young Jun Kim; David Osoba
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

9.  Treatment implications for radiation-induced nausea and vomiting in specific patient groups.

Authors:  J-C Horiot; M Aapro
Journal:  Eur J Cancer       Date:  2004-05       Impact factor: 9.162

10.  A one-item question with a Likert or Visual Analog Scale adequately measured current anxiety.

Authors:  Heather M Davey; Alexandra L Barratt; Phyllis N Butow; Jonathan J Deeks
Journal:  J Clin Epidemiol       Date:  2006-12-27       Impact factor: 6.437

View more
  26 in total

1.  International radiation oncology trainee decision making in the management of radiotherapy-induced nausea and vomiting.

Authors:  Kristopher Dennis; Liying Zhang; Stephen Lutz; Yvette van der Linden; Angela van Baardwijk; Tanya Holt; Jean-Leon Lagrange; Palmira Foro-Arnalot; Lea-Choung Wong; Ernesto Maranzano; Kam-Hung Wong; Rico Liu; Vassilios Vassiliou; Benjamin W Corn; Carlo De Angelis; Lori Holden; C Shun Wong; Edward Chow
Journal:  Support Care Cancer       Date:  2013-02-26       Impact factor: 3.603

Review 2.  2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.

Authors:  Christina H Ruhlmann; Franziska Jahn; Karin Jordan; Kristopher Dennis; Ernesto Maranzano; Alexander Molassiotis; Fausto Roila; Petra Feyer
Journal:  Support Care Cancer       Date:  2016-09-13       Impact factor: 3.603

3.  Symptom clusters of gastrointestinal cancer patients undergoing radiotherapy using the Functional Living Index-Emesis (FLIE) quality-of-life tool.

Authors:  Michael Poon; Kristopher Dennis; Carlo DeAngelis; Hans Chung; Jordan Stinson; Liying Zhang; Gillian Bedard; Erin Wong; Marko Popovic; Nicholas Lao; Natalie Pulenzas; Shun Wong; Paul Cheon; Edward Chow
Journal:  Support Care Cancer       Date:  2015-01-27       Impact factor: 3.603

4.  Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy.

Authors:  Ingeborg Fraunholz; Katharina Grau; Christian Weiss; Claus Rödel
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

5.  Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study.

Authors:  Carlo Pirri; Paul Katris; James Trotter; Evan Bayliss; Robert Bennett; Peter Drummond
Journal:  Support Care Cancer       Date:  2010-09-03       Impact factor: 3.603

6.  A novel prospective descriptive analysis of nausea and vomiting among patients receiving gastrointestinal radiation therapy.

Authors:  Michael Poon; Jonathan Hwang; Kristopher Dennis; Carlo DeAngelis; Liying Zhang; Hans Chung; Jordan Stinson; Shun Wong; Natalie Pulenzas; Edward Chow
Journal:  Support Care Cancer       Date:  2015-09-16       Impact factor: 3.603

7.  Impact of radiation-induced nausea and vomiting on quality of life.

Authors:  Caitlin Yee; Leah Drost; Liying Zhang; Bo Angela Wan; Vithusha Ganesh; May Tsao; Elizabeth Barnes; Mark Pasetka; Carlo DeAngelis; Edward Chow
Journal:  Support Care Cancer       Date:  2018-05-28       Impact factor: 3.603

8.  Patients' Perspectives on Integrating Acupuncture into the Radiation Oncology Setting.

Authors:  Eitan Frankel; Sheila Garland; Salimah H Meghani; Neha Vapiwala; Jun J Mao
Journal:  Eur J Integr Med       Date:  2014-10-01       Impact factor: 1.314

9.  Factors associated with weight loss during radiotherapy in patients with stage I or II head and neck cancer.

Authors:  Alice Nourissat; Isabelle Bairati; André Fortin; Michel Gélinas; Abdenour Nabid; François Brochet; Bernard Têtu; François Meyer
Journal:  Support Care Cancer       Date:  2011-03-20       Impact factor: 3.603

10.  Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases.

Authors:  Kristopher Dennis; Janet Nguyen; Roseanna Presutti; Carlo DeAngelis; May Tsao; Cyril Danjoux; Elizabeth Barnes; Arjun Sahgal; Lori Holden; Florencia Jon; Shun Wong; Edward Chow
Journal:  Support Care Cancer       Date:  2011-09-08       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.